BluePath’s initial acquisition expands its product and service offerings in the biopharmaceutical commercialization services sector. BluePath Solutions, a Los Angeles based health economics and value communication consulting firm announced today that...
Patients diagnosed with cancer may face significant financial toxicity, specifically out-of-pocket (OOP) costs related to medical care. Diagnosis and treatment of cancer at earlier stages may reduce this burden. To...
In a recently published microcosting analysis using trial healthcare resource utilization data, our colleagues estimated post-infusion costs with the chimeric antigen receptor (CAR) T cell therapy, idecabtagene vicleucel (ide-cel),...
Allogeneic hematopoietic cell transplantation (allo-HCT) has the potential for curative outcomes in a variety of hematologic malignancies but are often associated with adverse events, specifically chronic graft versus host disease...
Our colleagues recently participated in one of the first large-scale claims analyses to date on estimating the time to diagnosis across a range of cancer types. The recent article, published...
